Surfactant protein DNA methylation: A new entrant in the field of lung cancer diagnostics? (Review)

Mudit Vaid, Joanna Floros

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Lung cancer is a major cause of cancer-related mortality in both men and women. A 5-year survival of lung cancer patients is only 15% with a negative correlation between progressively advanced lung cancer stage and a 5-year survival period. The only chance for cure is surgical resection if done at the early stage of the disease. Therefore, an early diagnosis and a better prediction of prognosis could decrease mortality. An early diagnosis could provide the opportunity for a therapeutic intervention early in the course of the disease. Genetic alterations in the cancer genome include aneuploidy, deletions and amplifications of chromosomal regions, loss of heterozygosity (LOH), microsatellite alterations, point mutations and aberrant promoter methylation. Of the various types of genetic alterations (i.e. gene amplifications, allele deletions, point mutations or deletions and methylation) reported in different tumor types, aberrant promoter methylation of genes is recent and is the focus of the present review. Specifically, we will briefly review the role of promoter methylation in various malignancies and then focus on lung cancer diagnosis and promoter gene methylation with emphasis on the methylation status of genes of the innate host defense, namely the surfactant proteins A and D.

Original languageEnglish (US)
Pages (from-to)3-11
Number of pages9
JournalOncology reports
Volume21
Issue number1
DOIs
StatePublished - Apr 23 2009

Fingerprint

DNA Methylation
Surface-Active Agents
Methylation
Lung Neoplasms
Proteins
Point Mutation
Early Diagnosis
Pulmonary Surfactant-Associated Protein D
Pulmonary Surfactant-Associated Protein A
Genes
Neoplasms
Survival
Mortality
Gene Amplification
Sequence Deletion
Loss of Heterozygosity
Aneuploidy
Carcinogens
Microsatellite Repeats
Alleles

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{f5b59c858e1641dd8c2d6741f1a76f8f,
title = "Surfactant protein DNA methylation: A new entrant in the field of lung cancer diagnostics? (Review)",
abstract = "Lung cancer is a major cause of cancer-related mortality in both men and women. A 5-year survival of lung cancer patients is only 15{\%} with a negative correlation between progressively advanced lung cancer stage and a 5-year survival period. The only chance for cure is surgical resection if done at the early stage of the disease. Therefore, an early diagnosis and a better prediction of prognosis could decrease mortality. An early diagnosis could provide the opportunity for a therapeutic intervention early in the course of the disease. Genetic alterations in the cancer genome include aneuploidy, deletions and amplifications of chromosomal regions, loss of heterozygosity (LOH), microsatellite alterations, point mutations and aberrant promoter methylation. Of the various types of genetic alterations (i.e. gene amplifications, allele deletions, point mutations or deletions and methylation) reported in different tumor types, aberrant promoter methylation of genes is recent and is the focus of the present review. Specifically, we will briefly review the role of promoter methylation in various malignancies and then focus on lung cancer diagnosis and promoter gene methylation with emphasis on the methylation status of genes of the innate host defense, namely the surfactant proteins A and D.",
author = "Mudit Vaid and Joanna Floros",
year = "2009",
month = "4",
day = "23",
doi = "10.3892/or_00000182",
language = "English (US)",
volume = "21",
pages = "3--11",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

Surfactant protein DNA methylation : A new entrant in the field of lung cancer diagnostics? (Review). / Vaid, Mudit; Floros, Joanna.

In: Oncology reports, Vol. 21, No. 1, 23.04.2009, p. 3-11.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Surfactant protein DNA methylation

T2 - A new entrant in the field of lung cancer diagnostics? (Review)

AU - Vaid, Mudit

AU - Floros, Joanna

PY - 2009/4/23

Y1 - 2009/4/23

N2 - Lung cancer is a major cause of cancer-related mortality in both men and women. A 5-year survival of lung cancer patients is only 15% with a negative correlation between progressively advanced lung cancer stage and a 5-year survival period. The only chance for cure is surgical resection if done at the early stage of the disease. Therefore, an early diagnosis and a better prediction of prognosis could decrease mortality. An early diagnosis could provide the opportunity for a therapeutic intervention early in the course of the disease. Genetic alterations in the cancer genome include aneuploidy, deletions and amplifications of chromosomal regions, loss of heterozygosity (LOH), microsatellite alterations, point mutations and aberrant promoter methylation. Of the various types of genetic alterations (i.e. gene amplifications, allele deletions, point mutations or deletions and methylation) reported in different tumor types, aberrant promoter methylation of genes is recent and is the focus of the present review. Specifically, we will briefly review the role of promoter methylation in various malignancies and then focus on lung cancer diagnosis and promoter gene methylation with emphasis on the methylation status of genes of the innate host defense, namely the surfactant proteins A and D.

AB - Lung cancer is a major cause of cancer-related mortality in both men and women. A 5-year survival of lung cancer patients is only 15% with a negative correlation between progressively advanced lung cancer stage and a 5-year survival period. The only chance for cure is surgical resection if done at the early stage of the disease. Therefore, an early diagnosis and a better prediction of prognosis could decrease mortality. An early diagnosis could provide the opportunity for a therapeutic intervention early in the course of the disease. Genetic alterations in the cancer genome include aneuploidy, deletions and amplifications of chromosomal regions, loss of heterozygosity (LOH), microsatellite alterations, point mutations and aberrant promoter methylation. Of the various types of genetic alterations (i.e. gene amplifications, allele deletions, point mutations or deletions and methylation) reported in different tumor types, aberrant promoter methylation of genes is recent and is the focus of the present review. Specifically, we will briefly review the role of promoter methylation in various malignancies and then focus on lung cancer diagnosis and promoter gene methylation with emphasis on the methylation status of genes of the innate host defense, namely the surfactant proteins A and D.

UR - http://www.scopus.com/inward/record.url?scp=61449339824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449339824&partnerID=8YFLogxK

U2 - 10.3892/or_00000182

DO - 10.3892/or_00000182

M3 - Review article

C2 - 19082436

AN - SCOPUS:61449339824

VL - 21

SP - 3

EP - 11

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -